Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) was submitted on August 3, 2020, covering the month of August 2020. The report serves as a regulatory notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a capital structure notification.
| Capital Metric | Value as of July 31, 2020 |
|---|---|
| Issued Share Capital | 5,385,053,327 Ordinary Shares (25 pence each) |
| Treasury Shares | 367,705,950 Ordinary Shares |
| Total Voting Rights | 5,017,347,377 |
Material Changes
The filing does not disclose material changes in financial performance or operations compared to prior periods. It solely updates the denominator for shareholder interest calculations based on the share capital status as of July 31, 2020.
Guidance, Outlook, and Risks
The document contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. Its sole purpose is to inform shareholders of the total number of voting rights to assist in determining notification requirements under FCA rules.
Key Facts for Investor Verification
- Voting Rights Denominator: Shareholders should use 5,017,347,377 as the total number of voting rights for calculating interest thresholds.
- Treasury Holdings: Approximately 367.7 million shares are held in Treasury and do not carry voting rights.
- Reporting Date: The capital figures are accurate as of July 31, 2020.
- Regulatory Basis: This disclosure is mandated by the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.